United States Pancreatic cancer treatment market 2025: Industry Developments, Future Growth, Share & Industry Insights | Intelicure Lifesciences, Ipsen Pharma, Viatris Inc., Sun Pharmaceutical

Pancreatic cancer treatment market size reached US$ 5.09 billion in 2024 and is expected to reach US$ 9.65 billion by 2033, growing at a CAGR of 7.4% during the forecast period 2025-2033.

According to DataM Intelligence Comprehensive Report has released its latest report on the "pancreatic cancer treatment market Size 2025," providing a detailed analysis of market trends, key growth drivers, competitive landscape, and regional insights. The report includes market size (value and volume), CAGR projections, and emerging opportunities that help businesses identify growth areas and build effective strategies. Backed by data-driven insights and future outlook, this study serves as a valuable resource for companies looking to stay competitive and capitalize on market potential.

Get a Free Sample Research PDF: https://datamintelligence.com/download-sample/pancreatic-cancer-treatment-market?sg

USA - Industry Latest News 2025:

✅ 07 Jul 2025: Trial begins in the USA for Exact Therapeutics's Acoustic Cluster Therapy (ACT®) plus chemotherapy in locally advanced pancreatic cancer.

✅ 21 Oct 2025: MSK Cancer Center presents first‐report phase 1 data of dual‐targeted bispecific ADC (iza‐bren) in pancreatic cancer at European Society for Medical Oncology (ESMO)‐2025.

✅ 07 Nov 2025: Diakonos Oncology reports preliminary Phase 1 data of DOC1021, a patient‐specific dendritic‐cell immunotherapy in pancreatic ductal adenocarcinoma (PDAC).

✅ 12 Aug 2025: Bayer AG enters a deal worth up to US$1.3 billion with Kumquat Biosciences for a KRAS G12D inhibitor program covering pancreatic cancer among others.

Europe - Industry Latest News 2025:

✅ 08 Aug 2025: At American Society of Clinical Oncology 2025 (ASCO), emerging immunotherapy & targeted therapy combinations in pancreatic cancer were highlighted (novel immunotherapy + VEGF inhibitors).

✅ 13 Oct 2025: Ipsen SA reports its IPN01194 candidate (Phase I/IIa) in metastatic melanoma, colorectal and pancreatic adenocarcinoma - broadening their oncology pipeline.

✅ 19 Aug 2025: Anocca secures US$46 m to support its VIDAR‐1 Phase I/II pancreatic cancer therapy trial across four European countries.

Japan - Industry Latest News 2025:

✅ 21 Oct 2025: (Japan‐/Asia‐connected) The Takeda‐Innovent deal: Takeda Pharmaceutical Company Limited partners with Innovent Biologics to advance IBI343 into first‐line gastric and pancreatic cancer settings globally (outside Greater China).

✅ 07 Aug 2025: Japanese researchers report that a fermented stevia extract may kill pancreatic cancer cells in pre‐clinical work (lab/animals) - early science but novel.

Market Geographical Share:

North America holds a dominant position in the pancreatic cancer treatment market, accounting for a significant share due to advanced healthcare infrastructure, high adoption of innovative therapies, and strong funding for cancer research. The United States, in particular, is a key contributor owing to early detection programs, widespread awareness, and availability of targeted therapies and immunotherapies.

Europe represents a substantial market segment, with countries such as Germany, France, and the UK leading due to well-established oncology centers and progressive reimbursement policies. Increasing geriatric population and rising investments in cancer research contribute to steady market growth in this region.

The Asia-Pacific region is emerging as a high-growth market for pancreatic cancer treatment, fueled by increasing prevalence of lifestyle-related risk factors, expanding healthcare facilities, and government initiatives for cancer screening programs. Countries like Japan, China, and South Korea are seeing heightened adoption of advanced treatments, including minimally invasive surgeries and combination therapies.

Get Customization in the report as per your requirements: https://datamintelligence.com/customize/pancreatic-cancer-treatment-market?sg

Market Drivers:

✅ Rising Incidence and Mortality of Pancreatic Cancer:
Pancreatic cancer remains one of the most aggressive and lethal cancers, with late-stage diagnosis being common. This has created a substantial demand for effective treatment options, including chemotherapy, targeted therapies, and surgical interventions.

✅ Advancements in Therapeutic Technologies:
Continuous innovations in treatment modalities, such as immunotherapy, personalized medicine, and minimally invasive surgical techniques, are driving market growth. Novel drug developments and combination therapies are offering improved survival rates for patients.

✅ Increased Awareness and Early Diagnosis Initiatives:
Efforts by governments and healthcare organizations to promote early detection through screening programs are contributing to higher diagnosis rates. Early-stage detection increases the likelihood of effective treatment, further fueling market demand.

✅ Rising Healthcare Expenditure:
Growing healthcare budgets and improved insurance coverage in developed and emerging markets enable broader access to advanced therapies, supporting market expansion.

✅ Collaborations and Research Funding:
Strategic collaborations between hospitals, research institutes, and pharmaceutical companies accelerate the development and availability of innovative pancreatic cancer treatments, creating new growth opportunities globally.

Segments Covered in the Beverage Premix Market:

By Cancer Type - Exocrine Tumors, Neuroendocrine Tumors

By Treatment Type - Chemotherapy, Targeted Therapies, Immunotherapies, Radiation Therapies, Other Treatments

Regional Analysis for Beverage Premix Market:

⇥ North America (U.S., Canada, Mexico)

⇥ Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)

⇥ Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)

⇥ South America (Colombia, Brazil, Argentina, Rest of South America)

⇥ Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

Buy Now & Get 30% OFF - Grab 50% OFF on 2+ reports: https://www.datamintelligence.com/buy-now-page?report=pancreatic-cancer-treatment-market?sg

Major Key Players: Pfizer Inc., Eli Lilly and Company, Novartis AG, Bristol-Myers Squibb Company, AstraZeneca, Intelicure Lifesciences, Ipsen Pharma, Viatris Inc., Sun Pharmaceutical Industries Ltd, and F. Hoffmann-La Roche Ltd

✅ AstraZeneca: Focuses on pancreatic cancer among its hard‐to‐treat oncology portfolio (it lists pancreatic cancer explicitly as a target area).

✅ Intelicure Lifesciences: An Indian contract­manufacturing/CMO firm rather than a core value‐chain innovator; no publicly‐available market‐share figure in pancreatic‐cancer treatment, so its relevance is in manufacturing support rather than a direct branded competitor.

✅ Ipsen Pharma: While overall oncology sales are growing (12.1% YTD) the company doesn't publicly disclose a dedicated pancreatic cancer‐treatment market share in the sources found.

✅ Viatris Inc.: No specific, publicly‐disclosed pancreatic‐cancer treatment share was located from the sources; thus its role in this segment may be through generics/chemotherapy supply rather than branded differentiated therapies (based on available information).

✅ Sun Pharmaceutical Industries: Has direct activity in pancreatic‐cancer treatment via its INFUGEMTM (gemcitabine) ready‐to‐infuse injection, approved in the US for pancreatic cancer among indications.

Unlimited Insights. One Subscription: https://www.datamintelligence.com/reports-subscription

Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.
Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.